Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer

Global Cancer Statistics, 2002

Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,573 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works

Restoring function in exhausted CD8 T cells during chronic viral infection

Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 3,960 · see citing works

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,204 · see citing works

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · see citing works

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · see citing works

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · see citing works

The B7 family revisited

Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · see citing works

Japanese Classification of Gastric Carcinoma – 2nd English Edition –

Japanese Gastric Cancer Association (1998) · Gastric Cancer · doi:10.1007/pl00011681 · Cited by 2,182 · see citing works

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · see citing works

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,519 · see citing works

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 ⁺ T lymphocytes are prognostic factors of human ovarian cancer

Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · see citing works

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works

Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

Chen, L. (2004) · Nature reviews. Immunology · doi:10.1038/nri1349 · Cited by 1,257 · see citing works

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018 · see citing works

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

Brown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968 · see citing works

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

Kuang, D., Zhao, Q., Peng, C., Xu, J., Zhang, J., Wu, C. Y., & Zheng, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 897 · see citing works

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · see citing works

B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

Tseng, S.-Y., Otsuji, M., Gorski, K. S., Huang, X., Slansky, J. E., Pai, S. I., Shalabi, A., Shin, T., Pardoll, D. M., & Tsuchiya, H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.839 · Cited by 867 · see citing works

Tumor-infiltrating NY-ESO-1–specific CD8 ⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859 · see citing works

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776 · see citing works

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772 · see citing works

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748 · see citing works

Immunostimulatory monoclonal antibodies for cancer therapy

Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 626 · see citing works

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 492 · see citing works

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 489 · see citing works

PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata: Associations with localized stage progression

Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22588 · Cited by 438 · see citing works

B7-H1 pathway and its role in the evasion of tumor immunity

Dong, H., & Chen, L. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0430-2 · Cited by 276 · see citing works

PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues

Keir, M. E., Freeman, G. J., & Sharpe, A. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5064 · Cited by 243 · see citing works

Hypermethylation of the APC (adenomatous Polyposis Coli) gene promoter region in human colorectal carcinoma

Hiltunen, M., Alhonen, L. I., Koıstınaho, J., Myöhänen, S., Pääkkönen, M. E., Marin, S., Kosma, V.-M., & Jänne, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970317)70:6 · Cited by 192 · see citing works

Tumor Antigens

Urban, J. L., & Schreiber, H. W. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.003153 · Cited by 143 · see citing works

Serum interleukin-6 and -10 levels in patients with gastric cancer

Ikeguchi, M., Hatada, T., Yamamoto, M., Miyake, T., Matsunaga, T., Fukumoto, Y., Yamada, Y., Fukuda, K., Saito, H., & Tatebe, S. (2009) · Gastric Cancer · doi:10.1007/s10120-009-0509-8 · Cited by 116 · see citing works

The expression of tumor-rejection antigen “MAGE” genes in human gastric carcinoma

Inoue, H., Mori, M., Honda, M., Li, J., Shibuta, K., Koushi, M., Ueo, H., & Akiyoshi, T. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90639-8 · Cited by 94 · see citing works

Interleukin‐10 expression significantly correlates with minor CD8+ T‐cell infiltration and high microvessel density in patients with gastric cancer

Sakamoto, T., Saito, H., Tatebe, S., Tsujitani, S., Ozaki, M., Ito, H., & Ikeguchi, M. (2005) · International Journal of Cancer · doi:10.1002/ijc.21598 · Cited by 49 · see citing works

Microarray Analysis Reveals Differences in Gene Expression of Circulating CD8+ T Cells in Melanoma Patients and Healthy Donors

Xu, T., Shu, C.-T., Purdom, E. A., Dang, D., Ilsley, D. D., Guo, Y., Weber, J. S., Holmes, S., & Lee, P. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3396 · Cited by 24 · see citing works

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works

T-cell exhaustion in the tumor microenvironment

Jiang, Y., Li, Y., & Zhu, B. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.162 · Cited by 1,151 · see citing works

Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers

Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 367 · see citing works

PD-1 and its ligands are important immune checkpoints in cancer

Dong, Y., Sun, Q., & Zhang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 336 · see citing works

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer

Muenst, S. E., Soysal, S. D., Gao, F., Obermann, E. C., Oertli, D., & Gillanders, W. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2581-3 · Cited by 332 · see citing works

Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response

Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 256 · see citing works

PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection

Macfarlane, A. W., Jillab, M., Plimack, E. R., Hudes, G. R., Uzzo, R. G., Litwin, S., Dulaimi, E., Al‐Saleem, T., & Campbell, K. S. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0133 · Cited by 177 · see citing works

Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer

Lazăr, D. C., Avram, M. F., Romosan, I., Cornianu, M., Tăban, S. M., & Goldiș, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i32.3583 · Cited by 144 · see citing works

Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment

Xie, Q., Ding, J. P., & Chen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.027 · Cited by 148 · see citing works

Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection

Eto, S., Yoshikawa, K., Nishi, M., Higashijima, J., Tokunaga, T., Nakao, T., Kashihara, H., Takasu, C., Iwata, T., & Shimada, M. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0519-7 · Cited by 142 · see citing works

Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms

Gholami, M. D., Kardar, G. A., Saeedi, Y., Heidari, S., Garssen, J., & Falak, R. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.002 · Cited by 140 · see citing works

Increased regulatory B cells are involved in immune evasion in patients with gastric cancer

Murakami, Y., Saito, H., Shimizu, S., Kono, Y., Shishido, Y., Miyatani, K., Matsunaga, T., Fukumoto, Y., Ashida, K., Sakabe, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49581-4 · Cited by 129 · see citing works

Inhibition of IL‐6‐JAK/Stat3 signaling in castration‐resistant prostate cancer cells enhances the NK cell‐mediated cytotoxicity via alteration of PD‐L1/NKG2D ligand levels

Xu, L., Chen, X., Shen, M., Yang, D., Fang, L., Weng, G., Tsai, Y., Keng, P. C., Chen, Y., & Lee, S. O. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12135 · Cited by 129 · see citing works

Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer

Luo, X., Peng, X., Hou, J., Wu, S., Shen, J., & Wang, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s137245 · Cited by 107 · see citing works

CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer

Su, S., Zou, Z., Chen, F., Ding, N., Du, J., Shao, J., Li, L., Fu, Y. S., Hu, B., Yang, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1249558 · Cited by 99 · see citing works

Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade

Jones, K. I., Tiersma, J. F., Yuzhalin, A. E., Gordon-Weeks, A. N., Buzzelli, J. N., Im, J. H., & Muschel, R. J. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809342 · Cited by 97 · see citing works

The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment

Bolandi, N., Derakhshani, A., Hemmat, N., Baghbanzadeh, A., Asadzadeh, Z., Nour, M. A., Brunetti, O., Bernardini, R., Silvestris, N., & Baradaran, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910719 · Cited by 96 · see citing works

Tumor antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer

Xu, L., Yang, L., Yao, D., Wu, X., Li, J., Liu, X., Deng, L., Huang, C., Wang, Y., Li, D., et al. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.01.001 · Cited by 92 · see citing works

The Crosstalk between Microbiome and Immune Response in Gastric Cancer

Nasr, R., Shamseddine, A. I., Mukherji, D., Nassar, F. J., & Temraz, S. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186586 · Cited by 91 · see citing works

Beyond Melanoma: Inhibiting The PD-1/PD-L1 Pathway in Solid Tumors

Gentzler, R. D., Hall, R. D., Kunk, P. R., Gaughan, E. M., Dillon, P. M., Slingluff, C. L., & Rahma, O. E. (2016) · Immunotherapy · doi:10.2217/imt-2015-0029 · Cited by 81 · see citing works

Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress

Myint, Z. W., & Goel, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0454-7 · Cited by 79 · see citing works

Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.

Raufi, A. G., & Klempner, S. J. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.037 · Cited by 75 · see citing works

PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment

Mathios, D., Ruzevick, J., Jackson, C. M., Xu, H., Shah, S. R., Taube, J. M., Burger, P. C., McCarthy, E. F., Quiñones‐Hinojosa, A., Pardoll, D. M., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1637-5 · Cited by 74 · see citing works

Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition

Li, Y., Shen, M., Xu, L. J., Yang, X., Tsai, Y., Keng, P. C., Chen, Y., & Lee, S. O. (2017) · Scientific Reports · doi:10.1038/s41598-017-08483-z · Cited by 56 · see citing works

Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression

Saito, H., Kono, Y., Murakami, Y., Shishido, Y., Kuroda, H., Matsunaga, T., Fukumoto, Y., Osaki, T., Ashida, K., & Fujiwara, Y. (2018) · Anticancer Research · doi:10.21873/anticanres.12197 · Cited by 50 · see citing works

Tumor-infiltrating CD4+ T cells in patients with gastric cancer

Yuan, L., Xu, B., Yuan, P., Zhou, J., Qin, P., Han, L., Chen, G., Wang, Z., Run, Z., Zhao, P., et al. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0489-4 · Cited by 49 · see citing works

Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients

Kono, Y., Saito, H., Miyauchi, W., Shimizu, S., Murakami, Y., Shishido, Y., Miyatani, K., Matsunaga, T., Fukumoto, Y., Nakayama, Y., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6629-6 · Cited by 48 · see citing works

Upregulation of Immune Checkpoint Molecules, PD-1 and LAG-3, on CD4+ and CD8+ T Cells after Gastric Cancer Surgery.

Takaya, S., Saito, H., & Ikeguchi, M. (2015) · PubMed Central · Cited by 43 · see citing works

Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials

Abdel-Rahman, O. M. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.015 · Cited by 39 · see citing works

PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers

Ying, L., Yan, F., Meng, Q., Yu, L., Yuan, X., Gantier, M. P., Williams, B. R. G., Chan, D. W., Shi, L., Tu, Y., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433520 · Cited by 38 · see citing works

Skin resident memory CD8+ T cells are phenotypically and functionally distinct from circulating populations and lack immediate cytotoxic function

Seidel, J. A., Vukmanovic‐Stejic, M., Müller-Durovic, B., Patel, N. P., Fuentes‐Duculan, J., Henson, S. M., Krueger, J. G., Rustin, M. H. A., Nestle, F. O., Lacy, K. E., et al. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13189 · Cited by 38 · see citing works

Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry

Ying, L., Yan, F., Meng, Q., Yuan, X., Yu, L., Williams, B. R. G., Chan, D. W., Shi, L., Tu, Y., Ni, P., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1311-8 · Cited by 35 · see citing works

PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer

Shen, Y., Teng, Y., Lv, Y.-P., Zhao, Y., Qiu, Y., Chen, W., Wang, L., Wang, Y., Mao, F., Cheng, P., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000422 · Cited by 33 · see citing works

Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond

Lin, E. M., Gong, J., Klempner, S. J., & Chao, J. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i25.2686 · Cited by 32 · see citing works

Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma

Kollmann, D., Ignatova, D., Jedamzik, J., Chang, Y., Jomrich, G., Paireder, M., Kristo, I., Kazakov, D. V., Michal, M., Cozzio, A., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5858-7 · Cited by 31 · see citing works

Expression and clinical significance of programmed death‑1 on lymphocytes and programmed death ligand‑1 on monocytes in the peripheral blood of patients with cervical cancer

Zhang, Y., Zhu, W., Zhang, X., Qu, Q., & Zhang, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.7105 · Cited by 30 · see citing works

Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma

Tagawa, M., Maekawa, N., Konnai, S., & Takagi, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150030 · Cited by 30 · see citing works

Altered frequency of CD8 + CD11c + T cells and expression of immunosuppressive molecules in lymphoid organs of mouse model of colorectal cancer

Rostamzadeh, D., Haghshenas, M. R., Daryanoosh, F., Samadi, M., Hosseini, A., Ghaderi, A. A., Mojtahedi, Z., & Babaloo, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27856 · Cited by 29 · see citing works

Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development

Abozeid, M., Rosato, A., & Sommaggio, R. (2017) · BioMed Research International · doi:10.1155/2017/5791262 · Cited by 25 · see citing works

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer

Zgodziński, W., Grywalska, E., Zinkiewicz, K., Surdacka, A., Majewski, M., Zakościelny, A., Bury, P., Roliński, J., & Wallner, G. T. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.75092 · Cited by 23 · see citing works

Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy

Lu, F., Hou, L., Wang, S., Yu, Y., Zhang, Y., Sun, L., Wang, C., Ma, Z., & Yang, F. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1927246 · Cited by 21 · see citing works

Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy

Ghaderi, S. S., Riazi‐Rad, F., Qamsari, E. S., Bagheri, S., Jamnani, F. R., & Sharifzadeh, Z. (2022) · BMC Biotechnology · doi:10.1186/s12896-022-00752-8 · Cited by 20 · see citing works

Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer

Hosseinzadeh, S., Imani, M., Pourfarzi, F., Jafari, N., Abediankenari, S., & Safarzadeh, E. (2024) · Medical Oncology · doi:10.1007/s12032-024-02326-4 · Cited by 20 · see citing works

Programmed Death-1 & its Ligands: Promising Targets for Cancer Immunotherapy

Shrimali, R. K., Janik, J. E., Eid, R. A., Mkrtichyan, M., & Khleif, S. N. (2015) · Immunotherapy · doi:10.2217/imt.15.49 · Cited by 20 · see citing works

The Emerging Role of Immunotherapy in Gastric and Esophageal Adenocarcinoma

Bockorny, B., & Pectasides, E. (2016) · Future Oncology · doi:10.2217/fon-2016-0103 · Cited by 17 · see citing works

Recent updates of precision therapy for gastric cancer: Towards optimal tailored management

Joo, M. K., Park, J., & Chun, H. J. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i19.4638 · Cited by 17 · see citing works

Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis

Däster, S., Eppenberger‐Castori, S., Mele, V., Schäfer, H. M., Schmid, L. A., Weixler, B., Soysal, S. D., Droeser, R. A., Spagnoli, G. C., Kettelhack, C., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00144 · Cited by 16 · see citing works

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer

Liu, X., Yang, Z., Latchoumanin, O., & Qiao, L. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16658251 · Cited by 15 · see citing works

Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature

Matboli, M., El-Nakeep, S. A. K., Hossam, N., Habieb, A., Azazy, A. E., Ebrahim, A. E., Nagy, Z., & Abdel-Rahman, O. M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i26.5896 · Cited by 15 · see citing works

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma

Ju, F., Wang, D., Huang, L. J., Jiang, C., Gao, C., Xiong, C., & Zhai, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1227756 · Cited by 13 · see citing works

Regulation of the CD8⁺ T cell and PDL1/PD1 axis in gastric cancer: Unraveling the molecular landscape

Yong, X., Mu, D., Ni, H., Wang, X., Zhang, T., Chang, X., he, S. T., & Zhou, D. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104750 · Cited by 12 · see citing works

Investigating T Cell Immune Dynamics and IL-6’s Duality in a Microfluidic Lung Tumor Model

Sardarabadi, P., Lee, K., Sun, W.-L., Kojabad, A. A., & Liu, C. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c09065 · Cited by 11 · see citing works

Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer

Sunakawa, Y., Cao, S., Volz, N. B., Berger, M. D., Yang, D., Parekh, A., Zhang, W., Matsusaka, S., Ning, Y., Stremitzer, S., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.46 · Cited by 11 · see citing works

Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of PD‐L1 mRNA and soluble PD‐L1

Yu, F., Jing, C., Yu, X., Cao, X., & Xu, C. (2020) · Hematological Oncology · doi:10.1002/hon.2758 · Cited by 11 · see citing works

PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers

Malinowska, K., Kowalski, A., Merecz-Sadowska, A., Paprocka-Zjawiona, M., Sitarek, P., Kowalczyk, T., & Zielińska‐Bliźniewska, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12052033 · Cited by 9 · see citing works

Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma

Sinnadurai, M., & McDonald, K. L. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2390-3 · Cited by 9 · see citing works

Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications

Piao, M., Zhang, N., Li, J., Li, C., Xun, Z., Zhang, L., Wang, S., Sun, B., Li, S., Xu, Y., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114052 · Cited by 9 · see citing works

Surface CD200 and CD200R antigens on lymphocytes in advanced gastric cancer: a new potential target for immunotherapy

Zgodziński, W., Grywalska, E., Surdacka, A., Zinkiewicz, K., Majewski, M., Szczepanek, D., Wallner, G. T., & Roliński, J. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.73398 · Cited by 9 · see citing works

The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment

Afshari, F., Soleymanjahi, S., Keshavarz‐Fathi, M., Roviello, G., & Rezaei, N. (2019) · Immunotherapy · doi:10.2217/imt-2018-0093 · Cited by 9 · see citing works

T lymphocyte‑related immune response and immunotherapy in gastric cancer (Review)

Zhang, Z., Zhang, W., Liu, X., Yan, Y., & Fu, W. (2024) · Oncology Letters · doi:10.3892/ol.2024.14670 · Cited by 7 · see citing works

Evolving treatments for advanced gastric cancer: appraisal of the survival trend

Roberto, M., Romiti, A., Onesti, C. E., Zullo, A., Falcone, R., & Marchetti, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1184979 · Cited by 7 · see citing works

Immunoterapia z użyciem przeciwciał monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych

Malesa, A., Nowak, J., Skórka, K., Karp, M., & Giannopoulos, K. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0025 · Cited by 6 · see citing works

Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin’s lymphoma

Feng, X., Luo, X., Yang, Y., Fan, Y., & Ye, Q. (2023) · Medicine · doi:10.1097/md.0000000000035757 · Cited by 5 · see citing works

Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals

Li, S., Mizukoshi, E., Kawaguchi, K., Miura, M., Nishino, M., Shimakami, T., Arai, K., Yamashita, T., Sakai, Y., Yamashita, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911623 · Cited by 5 · see citing works

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer.

Kim, J. K., Kim, S., Shin, E., Jung, J., Choi, H., & Jun, K. (2019) · PubMed Central · doi:10.3892/ol.2019.10594 · Cited by 5 · see citing works

PD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors

Franco, M., Seixas, F., Pires, M. A., Alves, A., Santos, A. A. F., Marrinhas, C., Vilhena, H., Santos, J., Faísca, P., Dias‐Pereira, P., et al. (2025) · Veterinary Sciences · doi:10.3390/vetsci12080731 · Cited by 4 · see citing works

Optimisation of neoadjuvant pembrolizumab therapy for locally advanced MSI-H/dMMR colorectal cancer using data-driven delay integro-differential equations

Hawi, G., Kim, P., & Lee, P. P. (2025) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2025.112231 · Cited by 4 · see citing works

Landscape of four different stages of human gastric cancer revealed by single-cell sequencing

Tang, X.-S., Xu, C., Li, N., Zhang, J., & Tang, Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i2.97125 · Cited by 4 · see citing works

Physical activity attenuates PD-1/PD-L1 expression and enhances CD4⁺ T-cell function in COPD patients

Alfaro, E., Díaz‐García, E., García-Tovar, S., Galera, R., Casitas, R., Martínez-Cerón, E., Torres-Vargas, M., Padilla, J. M., Fernández, C. L., Pérez-Moreno, P., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-31223-7 · Cited by 3 · see citing works

Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism

Takahashi, R., Sato, Y., Kimishima, M., Shiohara, T., & Ohyama, M. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01732-8 · Cited by 3 · see citing works

Expression characteristics of peripheral lymphocyte programmed death 1 and FoxP3+ Tregs in gastric cancer during surgery and chemotherapy

Li, H., Cao, G.-M., Gu, G.-L., Li, S.-Y., Yan, Y., Fu, Z., & Du, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i40.5582 · Cited by 3 · see citing works

Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer

Zheng, C.-W., Yang, Y.-M., & Yang, H. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i9.3905 · Cited by 3 · see citing works

Bispecific antibodies: A promising entrant in cancer immunotherapy

Saini, S., & Kumar, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821972-0.00014-9 · Cited by 3 · see citing works

Immune Checkpoint Restoration as a Therapeutic Strategy to Halt Diabetes-Driven Atherosclerosis

Saha, D., Dutta, P., & Chakraborty, A. (2025) · Biology · doi:10.3390/biology14121731 · Cited by 2 · see citing works

Immune normalization strategy against suboptimal health status: safe and efficacious therapy using mixed-natural killer cells

Li, Y., Harunori, O., Fu, S., Xing, F., Wu, H., Wang, J., Chen, A., Ren, X., Peng, D., Xia, L., et al. (2021) · Aging · doi:10.18632/aging.203279 · Cited by 2 · see citing works

Myeloid-derived suppressor cells modulation in the context of tumor microenvironment for gastric cancer

Portillo‐Miño, J. D., Calderón, J. J., Ruíz‐García, E., & Monge, C. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03960-8 · Cited by 2 · see citing works

Immune Checkpoint Blockade and Gastric Cancer

Su, S., & Liu, B. (2017) · Springer eBooks · doi:10.1007/978-981-10-3978-2_9 · Cited by 2 · see citing works

Effect of operation-introducing hyperthermic intraperitoneal chemotherapy on cellular immune function in patients with adenocarcinoma of the esophagogastric junction

Nie, Z., Huang, Y., Li, S., & Li, L. (2021) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2021.09.028 · Cited by 2 · see citing works

Advances in translational therapy for locally advanced gastric cancer

Zhao, K., Na, Y., & Xu, H. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i11.2405 · Cited by 2 · see citing works

Role of Programmed Cell Death Receptor-1 and Cytotoxic T Lymphocyte-Associated Antigen 4 in Bovine Leukemia Virus Infection

(2023) · International Journal of Veterinary Science · doi:10.47278/journal.ijvs/2023.108 · Cited by 2 · see citing works

Modelling Immune Dynamics in Locally Advanced MSI-H/dMMR Colorectal Cancer with Neoadjuvant Pembrolizumab Treatment: From Differential Equations to an Agent-Based Framework

Hawi, G., Kim, P., & Lee, P. P. (2026) · Bulletin of Mathematical Biology · doi:10.1007/s11538-026-01594-7 · Cited by 1 · see citing works

Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers

Hwang, J. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.13 · Cited by 1 · see citing works

Clinical Implications of Molecular Heterogeneity of Gastric Cancer

Hudler, P., & Komel, R. (2017) · InTech eBooks · doi:10.5772/intechopen.69775 · Cited by 1 · see citing works

Effect of Radical Surgery for Advanced Adenocarcinoma of Esophagogastric Junction on Perioperative Cellular Cell Immunity

Li, S., Gong, Y.-X., Zhang, Z., Zhang, W., Liu, Z., & Li, B.-Z. (2019) · Journal of Investigative Surgery · doi:10.1080/08941939.2019.1606963 · Cited by 1 · see citing works

Lymph nodes may be a source for immunetherapy in gastric cancer

ASSUMPÇÃO, P. P., Canelas, É. T. C., Ramos, A. C., Anaissi, A. K. M., Acioli, J. F., Ishak, G., dos Santos, S. E. B., Demachki, S., & de Assumpção, P. P. (2020) · Oncotarget · doi:10.18632/oncotarget.27578 · Cited by 1 · see citing works

Immune Normalization Strategy Against Suboptimal Health Status: Safe and Effective Mixed-Natural Killer Cell TherapyPreprint

Li, Y., Fu, S., Xing, F., Wu, H., Wang, J., Chen, A., Ren, X., Peng, D., Xia, L., Shi, M., et al. (2020) · doi:10.21203/rs.3.rs-35479/v1 · Cited by 1 · see citing works

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection (TUM2P.881)

Macfarlane, A. W., Jillab, M., Plimack, E. R., Hudes, G. R., Uzzo, R. G., Litwin, S., Dulaimi, E., Al‐Saleem, T., & Campbell, K. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.192.supp.71.5

Immune Checkpoint Inhibitors: A Step forward in Cancer Management

Carratù, M. R., Potenza, M. A., Nacci, C., Rasmo, D. D., & Signorile, A. (2019) · Madridge Journal of Oncogenesis · doi:10.18689/mjo-1000112

A REVIEW OF MODERN IMMUNOTHERAPY IN GASTROINTESTINAL MALIGNANT TUMORS

Yusupbekov, A., Viktorovich, K. S., Adilkhodjaev, A. A., Islamov, K. J., & Egamberdiev, D. M. (2020) · EurasianUnionofScientists · doi:10.31618/esu.2413-9335.2020.6.74.762

Evaluation of the Relationship of PD-L1 and FOXP3 Expressions With Clinicopathological Parameters in Gastric Carcinomas

Sayhan, S., Dınız, G., Ayaz, D., Kahraman, D. S., Ayvat, P. U., & Çalık, B. (2021) · Forbes Journal of Medicine · doi:10.5222/forbes.2021.94840

ROLE OF MONOCLONAL ANTIBODIES AGAINST THE PROGRAMMABLE DEATH (PD-1) RECEPTOR OF T-CELLS IN TARGETED THERAPY OF MELANOMA

Mukantayev, K., Муканов, К. К., & Zhylkibayev, A. A. (2018) · Eurasian journal of applied biotechnology · doi:10.11134/btp.1.2018.3

Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients

Liu, L., Wang, L., Wang, W., Wang, Y., Yanrong, W., Xu, N., Li, N., & Liu, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1683486

Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer

Sivapiromrat, A. K., McAdams, M. J., Donahue, R. N., Celades, C., Lassoued, W., Bagheri, H., Bahiru, E., Swift, S., Feierabend, C., Sansone, S., et al. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.101019

An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer

Takano, S., Saito, H., & Ikeguchi, M. (2016) · Surgery Today · doi:10.1007/s00595-016-1305-9 · Cited by 42 · see citing works

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer.

Kim, J. K., Kim, S., Shin, E., Jung, J., Choi, H., & Jun, K. (2019) · PubMed Central · doi:10.3892/ol.2019.10594 · Cited by 5 · see citing works

Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer

Zgodziński, W., Grywalska, E., Zinkiewicz, K., Surdacka, A., Majewski, M., Zakościelny, A., Bury, P., Roliński, J., & Wallner, G. T. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.75092 · Cited by 23 · see citing works

Expression and clinical significance of PD-1 on CD8~+T cell in gastric cancer

Yong, Z. (2011) · Chinese Journal of Gastroenterology and Hepatology

PD-1 Expression on Circulating CD8+ T-Cells as a Prognostic Marker for Patients With Gastric Cancer

Saito, H., Shimizu, S., Kono, Y., Murakami, Y., Shishido, Y., Miyatani, K., Matsunaga, T., Fukumoto, Y., Ashida, K., & Fujiwara, Y. (2018) · Anticancer Research · doi:10.21873/anticanres.13132 · Cited by 23 · see citing works